Verrica Pharmaceuticals Inc. (VRCA) Misses Q3 EPS by 18c

Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) reported Q3 EPS of ($0.54), $0.18 worse than the analyst estimate of ($0.36). Revenue for the quarter came in at $2.92 million versus the consensus estimate of $454.07 thousand.

For earnings history and earnings-related data on Verrica Pharmaceuticals Inc. (VRCA) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• The LGL Group (LGL) Misses Q2 EPS by 8c
• Motorsport Games Inc. (MSGM) Tops Q2 EPS by 33c